A Decade of Engineering a Disease-Free World

The 10th CAR-TCR Summit!

The cell therapy field was facing one of its toughest climates when it came to investments in 2025. But, hope was not lost. The industry was rallying together to keep driving innovation in cell therapy efficacy, durability, streamlining manufacturing, potency understanding, reducing vein to vein time and navigating regulatory hurdles. For the 10th Anniversary of the CAR-TCR Summit attendees reflected on a decade of progress whilst engaging in solutions-driven discussions that empowered them to tackle cell therapy development challenges to help shape the future of the field.

Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharmathis meeting equipped you to overcome challenges across the entire development landscape - spanning durabilitymanufacturing timelinespotency assay matrixsolid tumor targetingbiomarker datahigh cost of goodsscale up and scale out, and more, to make rapid advancements in the clinic and beyond.

Whether your focus was on DiscoveryTranslationClinical DevelopmentEarly-Stage ManufacturingLate-Stage Manufacturing, or Analytical Development you gained in-depth insights across the entire cell therapy value chain.

I’m excited to join this year’s summit to exchange bold ideas, share first-in-human data on iNKT cell therapy, and explore how we can expand the reach of cell therapy to patients suffering from autoimmune diseases. It’s a critical moment for collaboration and scientific innovation as we move beyond oncology.

MiNK Therapeutics, 2025 Speaker

images (10)

View the Guide to the 2025 CAR-TCR Summit:

  • Get a full overview of the agenda, speakers, and sessions in one place
  • Preview featured case studies that we’ll be shining a light on CAR-TCR
  • Discover exclusive content such as keynote highlights, attendee benefits and more
  • Share easily with colleagues and decision-makers to mobilize interest
Screenshot 2026-03-26 144301

Key Highlights of the 10th CAR-TCR Summit:

Holistic Coverage of Multiple Cell Types

51% CAR-Ts, 20% TCRs, 18% NK, Gamma Delta, Macrophages, TILs and Tregs, and 11% multiple cell types to give full visibility of advancements in cell therapy

Comprehensive Coverage of Indications

Spanning haem, and solid tumors, to autoimmune indications - understand the challenges when targeting different indications from cell engineering to patient recruitment nuances

Brand New Biotech & Pharma Partnering Day

Join some of the key players involved in recent mergers and acquisitions, including AstraZeneca, Johnson & Johnson, and Merck, to gain insider insights into the decision-making processes

New Clinical Data

from Capstan Therapeutics on in vivo CAR-T, Legend Biotech on solid tumors targeting, and MiNK Therapeutics on the success of cell therapy beyond oncology

Full Cell Therapy Landscape Coverage

Gain competitive insight across multiple scopes of indications from oncology to autoimmune to cover the growing trial expansion and ensure you stay ahead of the curve

Official Partners

Screenshot 2026-03-26 144301
Quick Download

Attending Companies Include

17 (2)

Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.

11

Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

2 (1)

Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.